Aktienanalyse zu DarioHealth Corp (DRIO)DRIODarioHealth Corp

DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

DarioHealth Corp is currently not a strong buy due to its low current price of $2.42, which is near its 52-week low of $2.38. The RSI is extremely low at 9.69, indicating potential oversold conditions, but the company has reported significant losses, with a net loss of $7.92 million in Q2 2026. The upcoming earnings report on November 12 could provide more clarity on its financial health, but the risk of further declines remains high, especially with hedge funds increasing their selling activity by 109.67%.

2 analysts cover DRIO: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 13.50.